FOXO4-DRI Dosing: 1mg Senolytic Protocol

FOXO4-DRI is a first-in-class senolytic peptide that selectively eliminates senescent "zombie cells" by disrupting the FOXO4-p53 interaction. Developed at Erasmus University Medical Center, it reversed aspects of aging in mice by clearing these cells from tissues. No human clinical trials exist. This is not medical advice.

Quick Reference: Standard Protocol

Standard protocol: 1 mg subcutaneous in the morning, 5 days on / 2 days off, for 2-week courses. Repeat 2-3 times per year with 3-6 months rest between courses.

For the full FOXO4-DRI peptide profile, vendor pricing, and research overview, see our FOXO4-DRI peptide page.

Cycling: 2 Weeks On, 3-6 Months Off

Run 1 mg daily (5 on / 2 off) for 2 weeks. Then rest 3-6 months before the next course. Repeat 2-3 times per year.

The intermittent schedule reflects the "hit-and-clear" nature of senolytic therapy -- once apoptosis is triggered, the immune system needs time to phagocytose debris. Pulsed administration may also reduce off-target effects on non-senescent cells.

Enhanced Protocol (Community)

Some aggressive community protocols use weight-based dosing from the original mouse study:

The community weight-based protocol uses the direct mg/kg number from mice without allometric correction. Standard allometric scaling (BSA factor ~12.3) would suggest far lower human doses. The 1 mg cheat sheet standard is the conservative recommended starting point.

Cost note: At 2-5 mg/kg for a 75 kg individual (150-375 mg per injection), FOXO4-DRI becomes one of the most expensive peptide protocols due to both the high dose and D-amino acid synthesis costs.

Routes of Administration

Subcutaneous injection (standard): At the 1 mg cheat sheet dose, injection volume is small (0.2 mL). At higher community doses, large volumes may require splitting across 2-3 injection sites per session.

Reconstitution Quick Reference

Math: 10 mg / 2 mL = 5 mg/mL. For 1 mg: 1 / 5 = 0.2 mL = 20 units. One vial lasts 10 doses.

FOXO4-DRI is a large peptide and can denature with aggressive agitation -- swirl very gently. May take 5-10 minutes to dissolve. Protect from light. For step-by-step instructions, see the Reconstitution Calculator.

Where These Numbers Come From

Landmark study (Baar et al., 2017): Published in Cell, mice received 5 mg/kg IV on alternating days over ~3 weeks. Treated aged mice showed restored fur density, improved kidney function, increased fitness, and reduced senescence markers. FOXO4-DRI showed 11.73-fold selectivity for senescent over non-senescent cells in vitro.

Leydig cell aging (Zhang et al., 2020): FOXO4-DRI improved testosterone secretion in aged mice by targeting senescent Leydig cells.

Chondrocyte senescence (Zhu et al., 2021): Selectively removed senescent cells from human chondrocyte cultures, with implications for cartilage repair.

The scaling problem: Translating 5 mg/kg from mice to humans is complex. Standard allometric scaling would suggest a far lower human-equivalent dose. Community protocols using 2-5 mg/kg in humans are deliberate choices by early adopters, not FDA-guided conversions.

Stacking Protocols

Critical: Never combine multiple senolytics simultaneously. Allow adequate recovery between senolytic courses (minimum 4-6 weeks). Run each compound individually first. Monitor bloodwork (CBC, CMP, inflammatory markers) between courses.

Side Effects & Safety

• Injection site reactions -- redness, swelling, stinging (common with large-volume SC injections)
• Flu-like symptoms -- mild fever, fatigue, malaise 24-72 hours post-injection (possibly from immune clearance of apoptotic cells)
• GI discomfort -- nausea, mild digestive upset
• Temporary fatigue -- 1-3 days post-injection
• Off-target cell death (theoretical) -- no compound is perfectly selective; healthy cells with transiently elevated FOXO4 could be affected
• Immune burden (theoretical) -- rapid senescent cell clearance could overwhelm phagocytic system
• Avoid if: active infection, recent surgery/wound healing, immunocompromised, pregnancy, active cancer treatment

Frequently Asked Questions

What is the standard FOXO4-DRI dose?

1 mg subcutaneous in the morning, 5 days on / 2 days off, for 2-week courses repeated 2-3 times per year. Use a 10 mg vial with 2 mL BAC water -- 1 mg = 20 units.

How long is a FOXO4-DRI cycle?

2 weeks (5 on / 2 off), with 3-6 months rest between courses. Repeat 2-3 times per year.

Are there any human clinical trials?

No. All data is from cell culture and animal models. The Baar et al. 2017 mouse study is the primary reference.

Why is FOXO4-DRI so expensive?

49 amino acids, all D-amino acids. The D-retro-inverso design makes it protease-resistant but dramatically increases synthesis cost.

How is FOXO4-DRI different from dasatinib + quercetin?

D+Q uses a small-molecule drug + flavonoid targeting senescent cell anti-apoptotic pathways. FOXO4-DRI specifically disrupts the FOXO4-p53 interaction. Different mechanisms, both lack extensive human data.

Related Guides

• FOXO4-DRI Peptide Page -- Full profile, vendor pricing
• FOXO4-DRI Benefits -- 6 research-backed effects ranked by evidence
• FOXO4-DRI Results Timeline -- Realistic expectations from preclinical data
• Epitalon Dosing Guide -- Telomerase activation protocols
• GHK-Cu Dosing Guide -- Tissue remodeling and longevity
• Calculate Your FOXO4-DRI Cycle Cost -- estimate vials needed and total cost

References

For educational and research purposes only. This is not medical advice. FOXO4-DRI is a research compound with no approved medical use.